Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 3/2012

01.09.2012 | short review

Follow-up care for head and neck cancer patients

verfasst von: Markus Hambek, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

The major issue of the follow-up period is the early detection of recurrent and second tumors. Beside this, a team of specialized physicians and nurses should take care of the patient in terms of quality of life and rehabilitation. Follow-up appointments therefore should include physical examination with office-based endoscopy, ultrasonography, radiological imaging, dental evaluation, blood testing for TSH and EBV, voice and swallowing evaluation, pain management, QoL-Questionnaire, nutritional and psychological evaluation and treatment. Follow-up care should be managed by a multidisciplinary group of specialized and certified health care professionals in order to achieve the best results and outcome for the patients.
Literatur
1.
Zurück zum Zitat NCCN Guidelines™ Version 2.2011. Head and neck cancers. Online at nccn.org. NCCN Guidelines™ Version 2.2011. Head and neck cancers. Online at nccn.org.
2.
Zurück zum Zitat Grégoire V, Lefebvre JL, Licitra L, Felip E. EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2010;21(Suppl 5):v184–6 (PubMed PMID: 20555077). Grégoire V, Lefebvre JL, Licitra L, Felip E. EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2010;21(Suppl 5):v184–6 (PubMed PMID: 20555077).
3.
Zurück zum Zitat Deutsche Krebsgesellschaft. Kurzgefasste interdisziplinäre Leitlinien. Empfehlungen zur Diagnostik und Therapie maligner Erkrankungen. Verlag Zuckschwerdt; 2008. Deutsche Krebsgesellschaft. Kurzgefasste interdisziplinäre Leitlinien. Empfehlungen zur Diagnostik und Therapie maligner Erkrankungen. Verlag Zuckschwerdt; 2008.
4.
Zurück zum Zitat EORTC QLQ HN 35, Copyright 1995 EORTC quality of life Study Group, version 1.0. EORTC QLQ HN 35, Copyright 1995 EORTC quality of life Study Group, version 1.0.
5.
Zurück zum Zitat AWMF Leitlinie S1 Hals: Zustand nach Tumor-OP v. 11/2009. Online at www.awmf.org. AWMF Leitlinie S1 Hals: Zustand nach Tumor-OP v. 11/2009. Online at www.awmf.org.
6.
Zurück zum Zitat Al-Ibraheem A, Buck A, Krause BJ, Scheidhauer K, Schwaiger M. Clinical applications of FDG PET and PET/CT in head and neck cancer. J Oncol. 2009;2009:208725 (PubMed PMID: 19707528; PubMed Central PMCID:PMC2730473).PubMedCrossRef Al-Ibraheem A, Buck A, Krause BJ, Scheidhauer K, Schwaiger M. Clinical applications of FDG PET and PET/CT in head and neck cancer. J Oncol. 2009;2009:208725 (PubMed PMID: 19707528; PubMed Central PMCID:PMC2730473).PubMedCrossRef
7.
Zurück zum Zitat Klabbers BM, Lammertsma AA, Slotman BJ. The value of positron emission tomography for monitoring response to radiotherapy in head and neck cancer. Mol Imaging Biol. 2003;5(4):257–70 (Review. PubMed PMID: 14499141).PubMedCrossRef Klabbers BM, Lammertsma AA, Slotman BJ. The value of positron emission tomography for monitoring response to radiotherapy in head and neck cancer. Mol Imaging Biol. 2003;5(4):257–70 (Review. PubMed PMID: 14499141).PubMedCrossRef
8.
Zurück zum Zitat Ryan WR, Fee WE Jr, Le Q-T, Pinto HA. Positronemission tomography for surveillance of head and neck cancer. Laryngoscope. 2005;115(4):645–50.PubMedCrossRef Ryan WR, Fee WE Jr, Le Q-T, Pinto HA. Positronemission tomography for surveillance of head and neck cancer. Laryngoscope. 2005;115(4):645–50.PubMedCrossRef
9.
Zurück zum Zitat Abgral R, Querellou S, Potard G, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med. 2009;50(1):24–9.PubMedCrossRef Abgral R, Querellou S, Potard G, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med. 2009;50(1):24–9.PubMedCrossRef
10.
Zurück zum Zitat Wang Y-F, Liu R-S, Chu P-Y, et al. Positron emission tomography in surveillance of head and neck squamous cell carcinoma after definitive chemoradiotherapy. Head Neck. 2009;31(4):442–51.PubMedCrossRef Wang Y-F, Liu R-S, Chu P-Y, et al. Positron emission tomography in surveillance of head and neck squamous cell carcinoma after definitive chemoradiotherapy. Head Neck. 2009;31(4):442–51.PubMedCrossRef
11.
Zurück zum Zitat Cermik TF, Mavi A, Acikgoz G, Houseni M, Dadparvar S, Alavi A. FDG PET in detecting primary and recurrent malignant salivary gland tumors. Clin Nucl Med. 2007;32(4):286–91.PubMedCrossRef Cermik TF, Mavi A, Acikgoz G, Houseni M, Dadparvar S, Alavi A. FDG PET in detecting primary and recurrent malignant salivary gland tumors. Clin Nucl Med. 2007;32(4):286–91.PubMedCrossRef
12.
Zurück zum Zitat Alvarez Perez RM, Borrego Dorado I, Ruiz Franco-Baux JV, Vazquez Albertino RJ. Evaluation of efficacy and clinical impact of positron emission tomography with 18F fluoro-deoxyglucose in patients with suspicion of recurrent head and neck cancer or distant metastases. Rev Espanola deMedicina Nucl. 2007;26(1):30–9.CrossRef Alvarez Perez RM, Borrego Dorado I, Ruiz Franco-Baux JV, Vazquez Albertino RJ. Evaluation of efficacy and clinical impact of positron emission tomography with 18F fluoro-deoxyglucose in patients with suspicion of recurrent head and neck cancer or distant metastases. Rev Espanola deMedicina Nucl. 2007;26(1):30–9.CrossRef
13.
Zurück zum Zitat Salaun PY, Abgral R, Querellou S, et al. Does 18fluorofluorodeoxyglucose positron emission tomography improve recurrence detection in patients treated for head and neck squamous cell carcinoma with negative clinical follow-up? Head Neck. 2007;29(12):1115–20.PubMedCrossRef Salaun PY, Abgral R, Querellou S, et al. Does 18fluorofluorodeoxyglucose positron emission tomography improve recurrence detection in patients treated for head and neck squamous cell carcinoma with negative clinical follow-up? Head Neck. 2007;29(12):1115–20.PubMedCrossRef
14.
Zurück zum Zitat Goerres GW, Schmid DT, Bandhauer F, et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol. 2004;130(1):105–9.CrossRef Goerres GW, Schmid DT, Bandhauer F, et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol. 2004;130(1):105–9.CrossRef
15.
Zurück zum Zitat Kubota K, Yokoyama J, Yamaguchi K, et al. FDGPET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging. 2004;31(4):590–5.PubMedCrossRef Kubota K, Yokoyama J, Yamaguchi K, et al. FDGPET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging. 2004;31(4):590–5.PubMedCrossRef
16.
Zurück zum Zitat Welkoborsky HJ. Ultrasound usage in the head and neck surgeon’s office. Curr Opin Otolaryngol Head Neck Surg. 2009;17(2):116–21 (PubMed PMID: 19363347).PubMedCrossRef Welkoborsky HJ. Ultrasound usage in the head and neck surgeon’s office. Curr Opin Otolaryngol Head Neck Surg. 2009;17(2):116–21 (PubMed PMID: 19363347).PubMedCrossRef
17.
Zurück zum Zitat Yoon DY, Hwang HS, Chang SK, et al. CT, MR, US, (18)-F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Eur Radiol. 2008;19:634–42.PubMedCrossRef Yoon DY, Hwang HS, Chang SK, et al. CT, MR, US, (18)-F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Eur Radiol. 2008;19:634–42.PubMedCrossRef
18.
Zurück zum Zitat Roper B, Nuse N, Busch R, et al. Tissue characterization of locoregionally advanced head-and-neck squamous cell carcinoma (HNSCC) using quantified ultrasonography: a prospective phase II study on prognostic relevance. Radiother Oncol. 2007;85:48–57.PubMedCrossRef Roper B, Nuse N, Busch R, et al. Tissue characterization of locoregionally advanced head-and-neck squamous cell carcinoma (HNSCC) using quantified ultrasonography: a prospective phase II study on prognostic relevance. Radiother Oncol. 2007;85:48–57.PubMedCrossRef
19.
Zurück zum Zitat DeVita, VT, Hellman, S, Rosenberg, SA. Cancer: principles and practice of oncology. 8th Revised edn. Lippincott Williams & Wilkins; 2008. DeVita, VT, Hellman, S, Rosenberg, SA. Cancer: principles and practice of oncology. 8th Revised edn. Lippincott Williams & Wilkins; 2008.
20.
Zurück zum Zitat Logeman, JA. Evaluation and treatment of swallowing disorders. 2nd edn., Vol. 13. Austin: PRO-ED; 1998. Logeman, JA. Evaluation and treatment of swallowing disorders. 2nd edn., Vol. 13. Austin: PRO-ED; 1998.
21.
Zurück zum Zitat Dodds WJ, Stewart ET, Logemann JA. Physiology and radiology of the normal oral and pharyngeal phases of swallowing (comment). Am J Roentgenol. 1990;154(5):953. Dodds WJ, Stewart ET, Logemann JA. Physiology and radiology of the normal oral and pharyngeal phases of swallowing (comment). Am J Roentgenol. 1990;154(5):953.
22.
Zurück zum Zitat Recommendations of the American Speech-Language-Hearing Association. Available online at www.asha.org. Recommendations of the American Speech-Language-Hearing Association. Available online at www.asha.org.
23.
Zurück zum Zitat Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18(19):3339–45.PubMed Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18(19):3339–45.PubMed
24.
Zurück zum Zitat Logan RM, Stringer AM, Bowen JM, Yeoh AS, Gibson RJ, Sonis ST, et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models, and cytotoxic drugs. Cancer Treat Rev. 2007;33(5):448–60.PubMedCrossRef Logan RM, Stringer AM, Bowen JM, Yeoh AS, Gibson RJ, Sonis ST, et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models, and cytotoxic drugs. Cancer Treat Rev. 2007;33(5):448–60.PubMedCrossRef
Metadaten
Titel
Follow-up care for head and neck cancer patients
verfasst von
Markus Hambek, MD
Publikationsdatum
01.09.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0017-0

Weitere Artikel der Ausgabe 3/2012

memo - Magazine of European Medical Oncology 3/2012 Zur Ausgabe